Insmed Now Covered by JMP Securities (INSMD)
Equities researchers at JMP Securities initiated coverage on shares of Insmed (NASDAQ:INSMD) in a research report issued on Thursday, Analyst Ratings Network reports. The firm set a “market perform” rating on the stock.
Separately, analysts at Lazard Capital Markets raised their price target on shares of Insmed from $24.00 to $28.00 in a research note to investors on Friday, August 23rd. They now have a “buy” rating on the stock. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $21.90.
Insmed Incorporated (NASDAQ:INSMD) is a biopharmaceutical company specializing in recombinant protein drug development.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.